The prognosis and safety of continuous saline bladder irrigation in patients after transurethral resection of bladder tumors: a systematic review and meta-analysis of comparative study

被引:1
作者
Wang, Xiang [1 ]
Wang, Yan [3 ]
Che, Xuanyan [2 ]
Zhou, Zhongbao [2 ]
Cheng, Bo [1 ]
机构
[1] Tengzhou Cent Peoples Hosp, Dept Urol, Zaozhuang 277500, Tengzhou, Peoples R China
[2] Capital Med Univ, Beijing Tian Tan Hosp, Dept Urol, 119 South 4th Ring West Rd, Beijing 100070, Peoples R China
[3] Sixth Med Ctr PLA Gen Hosp, Dept Tradit Chinese Med, Beijing, Peoples R China
关键词
Continuous saline bladder irrigation; Immediate intravesical chemotherapy; Transurethral resection; Systematic review and meta-analysis; Bladder cancer; TRANSITIONAL-CELL CARCINOMA; INTRAVESICAL CHEMOTHERAPY; PROPHYLACTIC TREATMENT; CLINICAL-TRIALS; CANCER; RECURRENCE; GUIDELINES; COMPLICATION; THERAPY;
D O I
10.1007/s13304-023-01525-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
The prognosis and safety of continuous saline bladder irrigation (CSBI) after transurethral resection of bladder tumor (TURB) as an alternative method needs to be explored. A literature review and meta-analysis were performed by searching PubMed, EMBASE, Cochrane Library databases and original references of the included articles. PRISMA checklists were followed. We used the GRADEpro GDT to assess the certainty of evidence from the results of our meta-analysis. A total of eight articles including 1600 patients were studied. The results indicated that patients received CSBI after TURB had no statistical differences compared to the control group in the recurrence-free survival and progression-free survival. However, the CSBI group showed significant improvements compared to the control group in terms of the number of recurrences during follow-up and the period to first recurrence except for the number of tumor progression during follow-up. Furthermore, patients treated with CSBI did not show an inferior effect than those treated with immediate intravesical chemotherapy (IC) in respects of recurrence-free survival, progression-free survival, the number of recurrences during follow-up, the number of tumor progression during follow-up and the period to first recurrence. But the immediate IC group had a higher incidence than the CSBI group in terms of macrohematuria, micturition pain, frequency of urination, dysuria, retention and local toxicities. Patients treated with CSBI after TURB showed a significant improvement compared to the control group in terms of the number of recurrences during follow-up and the period to first recurrence. However, compared to immediate IC, CSBI did not show an inferior effect except for lower incidence of adverse reactions.PROSPERO registration number CRD42021247088.
引用
收藏
页码:1795 / 1806
页数:12
相关论文
共 37 条
  • [1] Population, Intervention, Comparison, Outcomes and Study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews
    Amir-Behghadami, Mehrdad
    Janati, Ali
    [J]. EMERGENCY MEDICINE JOURNAL, 2020, 37 (06) : 387 - 387
  • [2] European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
    Babjuk, Marko
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Mostafid, A. Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Roupret, Morgan
    Shariat, Shahrokh F.
    Sylvester, Richard
    Zigeuner, Richard
    Capoun, Otakar
    Cohen, Daniel
    Dominguez Escrig, Jose Luis
    Hernandez, Virginia
    Peyronnet, Benoit
    Seisen, Thomas
    Soukup, Viktor
    [J]. EUROPEAN UROLOGY, 2019, 76 (05) : 639 - 657
  • [3] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Capoun, Otakar
    Cohen, Daniel
    Comperat, Eva M.
    Hernandez, Virginia
    Kaasinen, Eero
    Palou, Joan
    Roupret, Morgan
    van Rhijn, Bas W. G.
    Shariat, Shahrokh F.
    Soukup, Viktor
    Sylvester, Richard J.
    Zigeuner, Richard
    [J]. EUROPEAN UROLOGY, 2017, 71 (03) : 447 - 461
  • [4] BELL MD, 1992, J FORENSIC SCI, V37, P1401
  • [5] Böhle Andreas, 2004, Int. braz j urol., V30, P353, DOI 10.1590/S1677-55382004000400021
  • [6] Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies
    Brausi, M
    Collette, L
    Kurth, K
    van der Meijden, AP
    Oosterlinck, W
    Witjes, JA
    Newling, D
    Bouffioux, C
    Sylvester, RJ
    [J]. EUROPEAN UROLOGY, 2002, 41 (05) : 523 - 530
  • [7] Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer
    Brocks, CP
    Büttner, H
    Böhle, A
    [J]. JOURNAL OF UROLOGY, 2005, 174 (03) : 1115 - 1118
  • [8] Perivesical inflammation after early mitomycin C instillation
    Cliff, AM
    Romaniuk, CS
    Parr, NJ
    [J]. BJU INTERNATIONAL, 2000, 85 (04) : 556 - 557
  • [9] Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions
    Cumpston, Miranda
    Li, Tianjing
    Page, Matthew J.
    Chandler, Jacqueline
    Welch, Vivian A.
    Higgins, Julian P. T.
    Thomas, James
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (10):
  • [10] Meta-analysis in clinical trials revisited
    DerSimonian, Rebecca
    Laird, Nan
    [J]. CONTEMPORARY CLINICAL TRIALS, 2015, 45 : 139 - 145